Understanding the Inqovi Label Information
The Inqovi label provides critical details about the drug's uses, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and clinical pharmacology. This information is essential for healthcare professionals prescribing and managing Inqovi, as well as for patients to understand their treatment.
What is Inqovi Approved For?
Inqovi (decitabine and cedazuridine) is approved for the treatment of adults with myelodysplastic syndromes (MDS), including previously treated or untreated, de novo or secondary MDS with all lineages and French-American-British (FAB) subtypes. It is also approved for patients with chronic myelomonocytic leukemia (CMML) [1].
How is Inqovi Administered and What is the Dosage?
Inqovi is an oral medication. The recommended dose is 100 mg of decitabine and 32 mg of cedazuridine administered orally once daily for five consecutive days in a 28-day cycle [1].
What are the Key Warnings and Precautions for Inqovi?
The Inqovi label highlights several important warnings and precautions. These include potential for myelosuppression, characterized by neutropenia, thrombocytopenia, and anemia, which may require dose interruption or reduction. Patients should be monitored for cytopenias [1].
Embryo-fetal toxicity is another significant concern. Inqovi can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised of the potential risk to a fetus and to use effective contraception [1].
Tumor Lysis Syndrome (TLS) may occur in patients treated with Inqovi. Patients at increased risk for TLS should be monitored and managed appropriately [1].
Potential for Vitamin B12 Deficiency with oral administration of cytidine nucleoside analogs like cedazuridine warrants monitoring [1].
What are the Common Adverse Reactions Associated with Inqovi?
The most common adverse reactions reported in patients treated with Inqovi include:
* Fatigue
* Constipation
* Decreased neutrophil count
* Diarrhea
* Nausea
* Pneumonia
* Decreased platelet count
* Cough
* Abdominal pain
* Decreased white blood cell count
* Mucosal inflammation
* Upper respiratory tract infection
* Fever
* Hypokalemia
* Headache
* Musculoskeletal pain
* Dizziness
* Hypomagnesemia
* Hypocalcemia
* Asthenia
* Decreased hemoglobin
* Sepsis
* Hypophosphatemia [1]
Serious adverse reactions observed include pneumonia, sepsis, and febrile neutropenia [1].
How Does Inqovi Interact with Other Drugs?
The Inqovi label advises caution with certain drug interactions. It is a substrate of P-glycoprotein (P-gp), and co-administration with P-gp inhibitors may increase cedazuridine plasma concentrations. Conversely, P-gp inducers may decrease cedazuridine plasma concentrations [1].
What is the Clinical Pharmacology of Inqovi?
Inqovi is a combination of decitabine, a hypomethylating agent, and cedazuridine, an inhibitor of cytidine deaminase. Cedazuridine inhibits the breakdown of decitabine by cytidine deaminase in the gastrointestinal tract, thereby increasing oral bioavailability of decitabine [1].
When Does Inqovi Patent Exclusivity Expire?
Information on the specific patent expiry dates for Inqovi can be found through specialized resources. For detailed patent information and exclusivity timelines, consulting DrugPatentWatch.com is recommended [2].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213568s000lbl.pdf
2. https://www.drugpatentwatch.com/